1,740$
2,35%
Echtzeit-Aktienkurs Immuron Ltd. (ADR)
Bid:
Ask:
Echtzeit-Chart der Immuron Ltd. (ADR) Aktie
Börsenkurse Immuron Ltd. (ADR)
| gettex | - | - | - | - | 1,450€ | -0,34% |
| Echtzeit Euro | - | - | - | - | 1,410€ | 3,68% |
| Echtzeit USD | - | - | - | - | 1,696$ | -0,21% |
| Tradegate | - | - | - | - | 1,445€ | 3,21% |
| Nasdaq | - | - | - | - | 1,740$ | 2,35% |
| Börse Frankfurt | - | - | - | - | 1,440€ | 5,88% |
| Börse Stuttgart | - | - | - | - | 1,400€ | 6,06% |
Fundamentaldaten der Immuron Ltd. (ADR) Aktie
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2024 [USD] | 3,21 Mio. | -4,09 Mio. | -4,55 Mio. | -0,80 | - | - | 3,09 |
| 2023 [USD] | 1,21 Mio. | -2,59 Mio. | -2,55 Mio. | -0,45 | - | - | 8,16 |
| 2022 [USD] | 0,55 Mio. | -2,26 Mio. | -2,07 Mio. | -0,36 | - | - | 17,86 |
| 2021 [USD] | 0,11 Mio. | -6,58 Mio. | -6,25 Mio. | -1,13 | - | - | 90,91 |
| 2020 [USD] | 1,69 Mio. | -2,17 Mio. | -1,96 Mio. | -0,45 | - | - | 4,59 |
| 2019 [USD] | 1,71 Mio. | -3,69 Mio. | -3,31 Mio. | -0,92 | - | - | 4,16 |
| 2018 [USD] | 1,43 Mio. | -3,77 Mio. | -2,33 Mio. | -0,71 | - | - | 4,35 |
| 2017 [USD] | 1,05 Mio. | -6,32 Mio. | -5,13 Mio. | -1,93 | - | - | 5,37 |
| 2016 [USD] | 0,84 Mio. | -5,36 Mio. | -3,19 Mio. | -1,66 | - | - | 4,14 |
| 2015 [USD] | 0,94 Mio. | -3,47 Mio. | -2,87 Mio. | -1,52 | - | - | 3,52 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. |
Profil der Immuron Ltd. (ADR) Aktie
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce on mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994, and is headquartered in Carlton, Australia.